Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Scientists find that human embryos are vulnerable to COVID

4

May 2026

Scientists find that human embryos are vulnerable to COVID

A University of California, Riverside study reports that cells in the earliest stages of human development could be susceptible to infection by SARS-CoV-2, which causes COVID-19, offering new insight into how the virus interacts with developing human tissues and why that may matter for pregnancy research.

New genomic study tracks rare blood disease in children

4

May 2026

New genomic study tracks rare blood disease in children

Aplastic anemia is a rare, life-threatening blood disorder where patients are unable to make enough blood cells due to the immune system's attack on blood stem cells. The condition can progress to myelodysplastic syndrome (MDS) and leukemia. A study led by scientists at St. Jude Children's Research Hospital, with multiple collaborating institutions, used state-of-the-art genomic techniques to profile 619 children and adults with aplastic anemia.

New tools for quicker and easier Mpox diagnosis

4

May 2026

New tools for quicker and easier Mpox diagnosis

Following the rise in monkeypox (Mpox) cases, particularly in countries where the disease had not traditionally been observed, the World Health Organization (WHO) declared a Public Health Emergency of International Concern in June 2022 and again in August 2024.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.